WO2009047799A1 - Forme posologique pharmaceutique à usage oral unitaire solide à haute dose de mycophénolate de sodium et son procédé de fabrication - Google Patents
Forme posologique pharmaceutique à usage oral unitaire solide à haute dose de mycophénolate de sodium et son procédé de fabrication Download PDFInfo
- Publication number
- WO2009047799A1 WO2009047799A1 PCT/IN2008/000651 IN2008000651W WO2009047799A1 WO 2009047799 A1 WO2009047799 A1 WO 2009047799A1 IN 2008000651 W IN2008000651 W IN 2008000651W WO 2009047799 A1 WO2009047799 A1 WO 2009047799A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- active agent
- composition according
- composition
- mycophenolate sodium
- dosage form
- Prior art date
Links
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 title claims abstract description 222
- 229960000951 mycophenolic acid Drugs 0.000 title claims abstract description 206
- 239000002552 dosage form Substances 0.000 title claims abstract description 128
- 238000000034 method Methods 0.000 title claims abstract description 38
- 230000008569 process Effects 0.000 title claims abstract description 15
- 239000007787 solid Substances 0.000 title abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 300
- 239000013543 active substance Substances 0.000 claims abstract description 144
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 57
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims abstract description 50
- 238000013265 extended release Methods 0.000 claims abstract description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 36
- 238000011282 treatment Methods 0.000 claims abstract description 33
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 238000009472 formulation Methods 0.000 claims abstract description 22
- 230000002265 prevention Effects 0.000 claims abstract description 20
- 229960003444 immunosuppressant agent Drugs 0.000 claims abstract description 19
- 230000001861 immunosuppressant effect Effects 0.000 claims abstract description 19
- 239000003018 immunosuppressive agent Substances 0.000 claims abstract description 19
- 210000000056 organ Anatomy 0.000 claims abstract description 15
- 230000002459 sustained effect Effects 0.000 claims abstract description 15
- 230000002035 prolonged effect Effects 0.000 claims abstract description 14
- 230000001404 mediated effect Effects 0.000 claims abstract description 13
- 230000001413 cellular effect Effects 0.000 claims abstract description 12
- 208000035475 disorder Diseases 0.000 claims abstract description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 10
- 238000011321 prophylaxis Methods 0.000 claims abstract description 10
- 238000001727 in vivo Methods 0.000 claims abstract description 8
- 239000003826 tablet Substances 0.000 claims description 89
- 229920000642 polymer Polymers 0.000 claims description 51
- 239000000463 material Substances 0.000 claims description 49
- -1 furcellaran Polymers 0.000 claims description 44
- 238000000576 coating method Methods 0.000 claims description 38
- 239000011248 coating agent Substances 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 27
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 19
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 19
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 claims description 17
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 17
- 238000013268 sustained release Methods 0.000 claims description 16
- 239000012730 sustained-release form Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 14
- 238000007726 management method Methods 0.000 claims description 14
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 14
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 14
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 14
- 229920001577 copolymer Polymers 0.000 claims description 13
- 210000001519 tissue Anatomy 0.000 claims description 12
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 10
- 239000000314 lubricant Substances 0.000 claims description 10
- 239000011159 matrix material Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 8
- 239000001856 Ethyl cellulose Substances 0.000 claims description 8
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 8
- 229920001249 ethyl cellulose Polymers 0.000 claims description 8
- 229920000591 gum Polymers 0.000 claims description 8
- 239000008188 pellet Substances 0.000 claims description 8
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 7
- 229920002125 Sokalan® Polymers 0.000 claims description 7
- 230000000181 anti-adherent effect Effects 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 239000008206 lipophilic material Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 6
- 229940049654 glyceryl behenate Drugs 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 6
- 239000011118 polyvinyl acetate Substances 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 229920002554 vinyl polymer Polymers 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 235000010980 cellulose Nutrition 0.000 claims description 5
- 230000003628 erosive effect Effects 0.000 claims description 5
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 239000000080 wetting agent Substances 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- 229920001817 Agar Polymers 0.000 claims description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 4
- 108010036949 Cyclosporine Proteins 0.000 claims description 4
- 229920000084 Gum arabic Polymers 0.000 claims description 4
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- 239000000205 acacia gum Substances 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 235000010419 agar Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 4
- 230000000845 anti-microbial effect Effects 0.000 claims description 4
- 239000003472 antidiabetic agent Substances 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 239000004067 bulking agent Substances 0.000 claims description 4
- 235000010418 carrageenan Nutrition 0.000 claims description 4
- 239000000679 carrageenan Substances 0.000 claims description 4
- 229920001525 carrageenan Polymers 0.000 claims description 4
- 229940113118 carrageenan Drugs 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 229960001265 ciclosporin Drugs 0.000 claims description 4
- 229930182912 cyclosporin Natural products 0.000 claims description 4
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 4
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 4
- 230000004968 inflammatory condition Effects 0.000 claims description 4
- 229920000831 ionic polymer Polymers 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 239000008185 minitablet Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 229920008347 Cellulose acetate propionate Polymers 0.000 claims description 3
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 229920006218 cellulose propionate Polymers 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 239000002702 enteric coating Substances 0.000 claims description 3
- 238000009505 enteric coating Methods 0.000 claims description 3
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 3
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 3
- 125000005395 methacrylic acid group Chemical group 0.000 claims description 3
- 229940014456 mycophenolate Drugs 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 230000009261 transgenic effect Effects 0.000 claims description 3
- KPAPHODVWOVUJL-UHFFFAOYSA-N 1-benzofuran;1h-indene Chemical compound C1=CC=C2CC=CC2=C1.C1=CC=C2OC=CC2=C1 KPAPHODVWOVUJL-UHFFFAOYSA-N 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 244000215068 Acacia senegal Species 0.000 claims description 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 229920002284 Cellulose triacetate Polymers 0.000 claims description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 2
- 206010013774 Dry eye Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 208000003807 Graves Disease Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000569 Gum karaya Polymers 0.000 claims description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 claims description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
- 208000012528 Juvenile dermatomyositis Diseases 0.000 claims description 2
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims description 2
- 208000004883 Lipoid Nephrosis Diseases 0.000 claims description 2
- 229920000161 Locust bean gum Polymers 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
- 229920003091 Methocel™ Polymers 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 239000005062 Polybutadiene Substances 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 241000934878 Sterculia Species 0.000 claims description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010047112 Vasculitides Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 claims description 2
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 239000000048 adrenergic agonist Substances 0.000 claims description 2
- 239000000674 adrenergic antagonist Substances 0.000 claims description 2
- 229920013820 alkyl cellulose Polymers 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- 230000003444 anaesthetic effect Effects 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 239000004004 anti-anginal agent Substances 0.000 claims description 2
- 230000001773 anti-convulsant effect Effects 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 230000003178 anti-diabetic effect Effects 0.000 claims description 2
- 230000003474 anti-emetic effect Effects 0.000 claims description 2
- 230000000843 anti-fungal effect Effects 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 2
- 230000002924 anti-infective effect Effects 0.000 claims description 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 2
- 230000001139 anti-pruritic effect Effects 0.000 claims description 2
- 230000000561 anti-psychotic effect Effects 0.000 claims description 2
- 230000001754 anti-pyretic effect Effects 0.000 claims description 2
- 230000000151 anti-reflux effect Effects 0.000 claims description 2
- 230000000767 anti-ulcer Effects 0.000 claims description 2
- 229940124345 antianginal agent Drugs 0.000 claims description 2
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 2
- 229940124346 antiarthritic agent Drugs 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000002111 antiemetic agent Substances 0.000 claims description 2
- 229960003965 antiepileptics Drugs 0.000 claims description 2
- 239000000504 antifibrinolytic agent Substances 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000002255 antigout agent Substances 0.000 claims description 2
- 229960002708 antigout preparations Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000003524 antilipemic agent Substances 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 229940125684 antimigraine agent Drugs 0.000 claims description 2
- 239000002282 antimigraine agent Substances 0.000 claims description 2
- 239000002579 antinauseant Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000000939 antiparkinson agent Substances 0.000 claims description 2
- 229940125688 antiparkinson agent Drugs 0.000 claims description 2
- 229940127218 antiplatelet drug Drugs 0.000 claims description 2
- 239000003908 antipruritic agent Substances 0.000 claims description 2
- 239000002221 antipyretic Substances 0.000 claims description 2
- 239000003435 antirheumatic agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 239000000305 astragalus gummifer gum Substances 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 230000035587 bioadhesion Effects 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 238000010322 bone marrow transplantation Methods 0.000 claims description 2
- 239000002327 cardiovascular agent Substances 0.000 claims description 2
- 229940125692 cardiovascular agent Drugs 0.000 claims description 2
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 2
- 229920003086 cellulose ether Polymers 0.000 claims description 2
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000008139 complexing agent Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 230000002124 endocrine Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 230000010437 erythropoiesis Effects 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000003527 fibrinolytic agent Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 230000002949 hemolytic effect Effects 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 2
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 claims description 2
- 230000000147 hypnotic effect Effects 0.000 claims description 2
- 229940126904 hypoglycaemic agent Drugs 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 210000004153 islets of langerhan Anatomy 0.000 claims description 2
- 235000010494 karaya gum Nutrition 0.000 claims description 2
- 239000000231 karaya gum Substances 0.000 claims description 2
- 229940039371 karaya gum Drugs 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 235000010420 locust bean gum Nutrition 0.000 claims description 2
- 239000000711 locust bean gum Substances 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 210000003061 neural cell Anatomy 0.000 claims description 2
- 229920001220 nitrocellulos Polymers 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 239000002357 osmotic agent Substances 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 229940127242 parasympathomimetic drug Drugs 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 230000000704 physical effect Effects 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 229920001603 poly (alkyl acrylates) Polymers 0.000 claims description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 2
- 229920001484 poly(alkylene) Polymers 0.000 claims description 2
- 229920000184 poly(octadecyl acrylate) Polymers 0.000 claims description 2
- 229920002857 polybutadiene Polymers 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 229920000182 polyphenyl methacrylate Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 2
- 239000004800 polyvinyl chloride Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 230000001624 sedative effect Effects 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 150000005846 sugar alcohols Chemical class 0.000 claims description 2
- 229940127230 sympathomimetic drug Drugs 0.000 claims description 2
- 229920001059 synthetic polymer Polymers 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 229960000103 thrombolytic agent Drugs 0.000 claims description 2
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 229920001305 Poly(isodecyl(meth)acrylate) Polymers 0.000 claims 1
- 229920000196 poly(lauryl methacrylate) Polymers 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 14
- 230000000069 prophylactic effect Effects 0.000 abstract description 9
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 36
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 28
- 235000019359 magnesium stearate Nutrition 0.000 description 14
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 14
- 238000004090 dissolution Methods 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 10
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 8
- 239000008199 coating composition Substances 0.000 description 7
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 7
- 229960004866 mycophenolate mofetil Drugs 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 235000011132 calcium sulphate Nutrition 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 229940083410 myfortic Drugs 0.000 description 5
- 239000006186 oral dosage form Substances 0.000 description 5
- 239000008184 oral solid dosage form Substances 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000001175 calcium sulphate Substances 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000010413 sodium alginate Nutrition 0.000 description 4
- 239000000661 sodium alginate Substances 0.000 description 4
- 229940005550 sodium alginate Drugs 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 2
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- 238000007909 melt granulation Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 235000019814 powdered cellulose Nutrition 0.000 description 2
- 229920003124 powdered cellulose Polymers 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 239000007892 solid unit dosage form Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- OZCMOJQQLBXBKI-UHFFFAOYSA-N 1-ethenoxy-2-methylpropane Chemical compound CC(C)COC=C OZCMOJQQLBXBKI-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- SJVGFKBLUYAEOK-SFHVURJKSA-N 6-[4-[(3S)-3-(3,5-difluorophenyl)-3,4-dihydropyrazole-2-carbonyl]piperidin-1-yl]pyrimidine-4-carbonitrile Chemical compound FC=1C=C(C=C(C=1)F)[C@@H]1CC=NN1C(=O)C1CCN(CC1)C1=CC(=NC=N1)C#N SJVGFKBLUYAEOK-SFHVURJKSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 229910021532 Calcite Inorganic materials 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IEPRKVQEAMIZSS-UHFFFAOYSA-N Di-Et ester-Fumaric acid Natural products CCOC(=O)C=CC(=O)OCC IEPRKVQEAMIZSS-UHFFFAOYSA-N 0.000 description 1
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- IEPRKVQEAMIZSS-WAYWQWQTSA-N Diethyl maleate Chemical compound CCOC(=O)\C=C/C(=O)OCC IEPRKVQEAMIZSS-WAYWQWQTSA-N 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229920003153 Eudragit® NE polymer Polymers 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- RTGDFNSFWBGLEC-UHFFFAOYSA-N Mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1CC=C(C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 229910002054 SYLOID® 244 FP SILICA Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229920002433 Vinyl chloride-vinyl acetate copolymer Polymers 0.000 description 1
- ZXRRHFSTAFVGOC-UHFFFAOYSA-N [AlH3].[K] Chemical compound [AlH3].[K] ZXRRHFSTAFVGOC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 150000001398 aluminium Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000002682 anti-psoriatic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical class [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- UBWYRXFZPXBISJ-UHFFFAOYSA-L calcium;2-hydroxypropanoate;trihydrate Chemical compound O.O.O.[Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O UBWYRXFZPXBISJ-UHFFFAOYSA-L 0.000 description 1
- ZHZFKLKREFECML-UHFFFAOYSA-L calcium;sulfate;hydrate Chemical compound O.[Ca+2].[O-]S([O-])(=O)=O ZHZFKLKREFECML-UHFFFAOYSA-L 0.000 description 1
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229940107810 cellcept Drugs 0.000 description 1
- 229920001727 cellulose butyrate Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940031954 dibutyl sebacate Drugs 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- IEPRKVQEAMIZSS-AATRIKPKSA-N diethyl fumarate Chemical compound CCOC(=O)\C=C\C(=O)OCC IEPRKVQEAMIZSS-AATRIKPKSA-N 0.000 description 1
- VKNUORWMCINMRB-UHFFFAOYSA-N diethyl malate Chemical compound CCOC(=O)CC(O)C(=O)OCC VKNUORWMCINMRB-UHFFFAOYSA-N 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000013563 matrix tablet Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940095674 pellet product Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000019353 potassium silicate Nutrition 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000010499 rapseed oil Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000009490 roller compaction Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000012176 shellac wax Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- LUPNKHXLFSSUGS-UHFFFAOYSA-M sodium;2,2-dichloroacetate Chemical compound [Na+].[O-]C(=O)C(Cl)Cl LUPNKHXLFSSUGS-UHFFFAOYSA-M 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Definitions
- the present invention relates to high dose solid unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium as active agent in an amount of from greater than about 720 mg to about 1500 mg, preferably from about 800 mg to about 1440 mg calculated as mycophenolic acid, and one or more pharmaceutically acceptable excipient(s).
- the dosage form compositions are meant for once-a-day or twice-a-day administration and provide the active agent in an extended release form which is released in a sustained manner in-vivo for a prolonged duration.
- the invention is also directed to process of manufacturing the high dose formulations, and prophylactic and/or therapeutic methods of using such dosage forms.
- composition of the present invention are easy to formulate, safe, effective and well-tolerated, and are useful for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the management of immune-mediated diseases (autoimmune diseases).
- autoimmune diseases immune-mediated diseases
- MPA Mycophenolic acid
- Mycophenolate sodium having a molecular weight of 342.32.
- Mycophenolate sodium is a white to off-white crystalline powder and is highly soluble in aqueous media at physiological pH and practically insoluble in 0.1N HCl.
- a derivative of MPA such as mycophenolate mofetil (MMF) had been introduced commercially in the United States and elsewhere under the brand name CellCept® as an immunosuppressant in the immediate release form as 250 mg capsules or 500 mg oral tablets for the treatment or prevention of organ or tissue transplant rejection.
- a pharmaceutical delayed release composition comprising mycophenolate sodium under the brand name Myfortic® has been approved for marketing in the United States.
- Myfortic® is available for oral use as delayed release (enteric coated) tablets containing 180 mg or 360 mg of mycophenolic acid.
- the recommended dose of Myfortic® is 720 mg administered twice daily (1440 mg total daily dose).
- MPA is required in daily doses in the order of 2.0 grams to as much as 3.5 or 4.0 grams per day or even 5.0 grams per day depending upon the patient and the disease state being treated.
- immediate release tablet compositions containing 500 mg equivalent of MPA a patient receiving a 3.0 gram daily dose is required to take six tablets each day, giving rise to patient" inconvenience and noncompliance.
- at least two tablets of the delayed release product (Myfortic®) needs to be administered twice daily which leads to patient compliance concerns. Therefore, a need still exists to provide single unit high dose oral formulations for MPA particularly in view of its relatively high daily doses.
- US Patent No. 5554384 discloses high dose pharmaceutical formulation preferably as a capsule comprising a therapeutically effective amount of an active agent selected from the group consisting of mycophenolate mofetil and mycophenolic acid, said active agent having been heated to a first temperature above its melting point, cooled to a second temperature below its melting point at which second temperature said active agent remained liquefied, and filled into a pharmaceutical dosage form while in said cooled liquefied state.
- an active agent selected from the group consisting of mycophenolate mofetil and mycophenolic acid
- the preferred formulations disclosed in the said patent comprise 96% w/w mycophenolate mofetil and 4% w/w croscarmellose sodium, most preferably in a size 1 hard gelatin capsule containing 500 mg active agent, in a size 0 hard gelatin capsule containing 750 mg active agent, or in a size 00 hard gelatin capsule containing 1000 mg active agent.
- Such types of formulations involve cumbersome manufacturing procedure and also require special equipments. Further, such compositions primarily provide an immediate release of the active agent, since the claimed process of preparing the formulation makes the incorporation of rate controlling polymeric materials very difficult.
- the said patent does not disclose any modified release composition such as a delayed or sustained release composition comprising mycophenolate sodium as active agent; nor does it disclose any compositions comprising a substantially high dose of mycophenolate sodium in a single unit dosage form particularly for providing extended release of the active agent.
- US Patent Nos. 5,455,045, 6,025,391 and 6,172,107 describe a pharmaceutical composition comprising a mycophenolate salt, the composition being adapted to prevent release of the mycophenolate salt in the stomach and to release the mycophenolate salt in the upper part of the intestinal tract.
- PCT Publication No. WO2006024479 discloses a composition comprising mycophenolic acid, a salt or a prodrug thereof in a modified release form. Such compositions are intended to improve the drug distribution in the intestine, and to delay the delivery of the drug substance to the intestinal tract. Multiparticulate systems such as granules, pellets, beads and minitablets are disclosed. Also disclosed are coated pellets and granules compressed into rapid disintegrating tablets. However no single unit dosage form either uncoated or coated for providing a sustained release of mycophenolate sodium particularly throughout the GIT is disclosed. Another PCT Publication No.
- WO2005034916 describes a composition comprising mycophenolic acid, a salt or a prodrug thereof in multiparticulate form such that the compositions disintegrate or dissolve in the mouth, stomach or small intestine to give multiparticles, wherein the multiparticles are enteric coated.
- PCT Publication No. WO20Q3032978 describe an enteric coated solid dosage form comprising a pharmacologically effective amount of mycophenolic acid or mycophenolate salt, wherein the mycophenolic acid or mycophenolate salt is present in an amount of from 20-95% by weight based on the total weight of the solid dosage form including the enteric coating.
- compositions described in said PCT publications comprise substantially low unit dose of mycophenolate sodium compared to the daily dose requirement for treatment/prophylaxis of a disease/disorder using the said active agent. Therefore more than one unit of the dosage form composition needs to be administered to a patient at a time and hence such composition lacks patient compliance. Further, such compositions also need to be administered more that once-a-day due to the lower single unit content of the active agent.
- compositions of present invention are preferably single unit dosage forms containing high dose of mycophenolate sodium which can be administered as a single dose once daily or twice daily, and provides an extended prophylactic and/or therapeutic concentration of the active agent devoid of any substantial toxicity, thus demonstrating a significant advancement over prior art.
- the inventors of the present invention have invented extended release high dose solid unit oral pharmaceutical dosage form compositions of mycophenolate sodium, characterized in that mycophenolate sodium is released in a sustained manner, alleviating or at least reducing the chances of causing any associated side effects without compromising the bioavailability of active agent. Further, the active agent mycophenolate sodium is well absorbed orally and and/or the variation of its absorbability is substantially alleviated when made into compositions according to the present invention.
- a high dosage strength solid unit oral dosage form e.g., a tablet of mycophenolate sodium having satisfactory dissolution and bioavailability has apparently not been successfully developed prior to the present invention. This may be due in part to the pH dependent solubility, poor compressibility, poor flow properties and low bulk density of the said drug which makes it difficult to be formulated into a solid single unit dosage form.
- the formulation of high dose solid unit dosage form comprising mycophenolate sodium theoretically requires the use of high quantities of excipients, especially rate controlling polymers particularly when a sustained release product is desired.
- the inventors of the present invention have done extensive research and experimentation to alleviate the drawbacks existing in the prior art and to develop novel high dose solid unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium having particularly desirable bioavailability characteristics and which are well-tolerated, stable, and convenient to administer, thus demonstrating a significant advancement over prior art.
- modified release compositions comprising mycophenolate sodium as the active agent in a high dose solid unit oral pharmaceutical dosage form for once-a-day or twice-a-day administration, wherein the said composition provides a better patient compliance by reducing the frequency of dosage form administration and/or, reducing the number of unit dosage form to be administered, and wherein the said compositions upon administration leads to lesser episodes of allograft or xenograft transplant rejections.
- the modified release composition may be in the form of an extended release composition providing a sustained release of the active agent throughout the gastrointestinal tract (GIT).
- It is a further objective of the present invention to provide high dose solid unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium as active agent in an amount of from greater than about 720 mg to about 1500 mg, preferably from greater than about 800 mg to about 1440 mg, more preferably about 1080 mg calculated as mycophenolic acid, and one or more pharmaceutically acceptable excipient(s).
- the dosage form compositions provide the active agent in an extended release form which is released in a sustained manner in-vivo for a prolonged duration.
- It is another objective of the present invention to provide high dose solid unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium as active agent in an amount of from greater than about 720 mg to about 1500 mg, preferably from greater than about 800 mg to about 1440 mg, more preferably about 1080 mg calculated as mycophenolic acid, and one or more pharmaceutically acceptable excipient(s), wherein the dosage form is coated using such composition which aids in providing a sustained release of the active agent.
- It is a preferred objective of the present invention to provide high dose solid unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium as active agent in an amount of about 1080 mg calculated as mycophenolic acid, and one or more pharmaceutically acceptable excipient(s), wherein the said active agent is present in an extended release form proving a sustained release of the active agent for a prolonged duration.
- It is another preferred objective of the present invention to provide high dose solid unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium as active agent in an amount of about 1080 mg calculated as mycophenolic acid, and one or more pharmaceutically acceptable excipient(s), wherein the total daily dose of mycophenolate sodium can be provided in a single unit dose such as a single once-a-day tablet or at the most two unit doses such as two tablets, are easier to manufacture and involves a low formulation cost.
- It is another objective of the present invention to provide high dose solid unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium as active agent, optionally alongwith one or more pharmaceutically acceptable excipient(s), wherein the said composition is made in the form of a single unit dosage form or' a multiple unit dosage form comprising greater than about 720 mg of active agent calculated as mycophenolic acid, and wherein the said single unit dosage form or a multiple unit dosage form is administrable at a dosing interval of at least about 12 hours.
- composition of the present invention which comprises treating mycophenolate sodium with one or more release controlling material(s), alongwith optionally one or more pharmaceutically acceptable excipient(s), and formulating into a suitable dosage form.
- composition of the present invention which comprises treating mycophenolate sodium with at least one release controlling material(s) optionally with one or more other pharmaceutically acceptable excipient(s), and formulating into a suitable dosage form.
- composition of the present invention for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated diseas ⁇ )/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the management of immune-mediated diseases (autoimmune diseases), which comprises administering to a subject in need thereof the composition comprising a pharmaceutically effective amount of the active agent mycophenolate sodium.
- autoimmune diseases immune-mediated diseases
- autoimmune diseases immune-mediated diseases
- It is yet another objective of the present invention to provide high dose solid unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium as active agent in an amount of from greater than about 720 mg to about 1500 mg, preferably from greater than about 800 mg to about 1440 mg, more preferably about 1080 mg calculated as mycophenolic acid, and one or more pharmaceutically acceptable excipient(s), wherein the said dosage form is used concomitantly or during therapy with at least one another immunosuppressant such as cyclosporine, and/or another active agent such as corticosteroid.
- novel high dose solid unit oral pharmaceutical dosage form compositions of the present invention such as a single once-a-day tablet comprising mycophenolate sodium possess particularly desirable bioavailability characteristics, are well-tolerated, stable, convenient to administer, easier to manufacture involving a low formulation cost, and are useful particularly for prevention or treatment of native or transgenic organ, tissue or cellular allograft transplant rejection, immune-mediated and/or inflammatory disease.
- the novel compositions are patient-friendly particularly for administration of mycophenolate sodium to pediatric/geriatric patients, and provide a simple and reliable posology for administration of mycophenolate sodium.
- the present invention provides modified release compositions comprising mycophenolate sodium as the active agent in a high dose solid unit oral pharmaceutical dosage form for once-a-day or twice-a- day administration.
- the novel compositions provide a better patient compliance by reducing the frequency of dosage form administration and also resulting in lesser episodes of allograft or xenograft transplant rejections.
- the present invention provides effective, safe and tolerable high dose solid unit oral pharmaceutical dosage form compositions of mycophenolate sodium wherein the total daily dose of mycophenolate sodium can be provided in a single unit dose such as a single once-a-day tablet or at the most two unit doses such as two tablets, are easier to manufacture, and involves a low formulation cost, and wherein the single unit dosage forms have particularly an acceptable size for oral administration.
- the development of a modified release composition particularly extended release dosage form for mycophenolate sodium is challenging due to the pH-dependent solubility of the drug i.e. high solubility of the drug in pH above 6.0 and poor solubility in pH below 6.0. Furthermore, it is challenging to develop extended release dosage forms of mycophenolate sodium comprising high dose of the active agent that are robust, and whose dissolution behavior does not depend on the state of digestion or dosage form transit through the gastrointestinal tract.
- the inventors of the present invention have been able to develop such high dose solid unit oral pharmaceutical dosage form compositions of mycophenolate sodium thus demonstrating a significant advancement over the prior art.
- the present invention provides a stable high dose solid unit oral extended release pharmaceutical dosage form compositions of mycophenolate sodium such as matrix tablets which could provide substantially linear drug release for a prolonged duration of time during the transit through varying pHs of the gastro-intestinal tract.
- Difficulties in formulation of oral solid dosage forms such as tablets comprising mycophenolate sodium can be for example due to the low bulk density of active agent resulting in e.g. low mechanical stability of the solid dosage form and/or unfavorable size particularly when a high amount of excipients is added to improve the mechanical stability properties. Tablets with inferior mechanical properties are liable to crumbling, edge chipping or breaking. These difficulties are even greater when it is intended to make an oral solid dosage form comprising a high dose of mycophenolate sodium particularly due to the high drug loading and scope for using a proportionately lesser quantity of excipients. Unfortunately use of lesser quantity of excipients makes it more difficult to obtain particularly a single unit compressed solid dosage form.
- the drug mycophenolate sodium possesses very poor flow properties, poor compressibility and also develops static charges while processing which makes the formulation of a dosage form all the more challenging.
- developing high dose modified release composition particularly extended release unit dosage forms such as tablet formulations for mycophenolate sodium is very challenging and requires extensive research and experimentation.
- the present invention provides easy, convenient and reproducible method to manufacture particularly single unit high dose extended release dosage forms comprising mycophenolate sodium.
- the dosage form composition of the present invention is preferably designed in such a manner that it will not restrict the drug release to certain GIT pHs; instead it will facilitate release of drug through different pHs, which is very important for a desirable extended release dosage form.
- the present invention provides pharmaceutically acceptable high dose oral solid dosage forms, e.g. in the form of tablets of mycophenolate sodium in an easily administrable size and mechanically stable form with a high drug loading.
- Oral dosage forms being particularly convenient to administer and stable, may be obtained, e.g. by preparation of tablets by compression methods. More specifically, the tablets of the invention may be prepared by granulation followed by compression methods.
- the present invention provides unit high dose modified release compositions comprising mycophenolate sodium as active agent suitable for use in situations where a sustained effect of said active agent for a prolonged duration is desirable in order to develop compositions suitable for administration less frequently such as once or twice daily.
- the compositions are also capable of providing an initial rapid effect followed by a sustained effect of the active agent for use in certain situations where such combined effect is desirable.
- the high dose solid unit oral pharmaceutical dosage form of the present invention when made into the modified release compositions are safe, predictable and reliable, and are also very storage stable because an immediate release due to accidental damaging of e.g. the coating or capsule may result in undesired high plasma concentrations, so-called dose dumping, which could cause undesired side effects.
- the storage stability of the extended release compositions of the present invention is very beneficial from a technical point of view since even a minor change in the release rate and/or release pattern may have a significant impact on the in-vivo performance of the composition.
- the modified release pharmaceutical composition has been disclosed which at the same time can be produced in an easy, cheap and reliable manner and which provides a suitable profile for release of active agent (under acidic, neutral and basic conditions) resulting in an extended period of about 12 to 24 hours.
- high dose single unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium as active agent, optionally alongwith one or more pharmaceutically acceptable excipient(s), wherein the said composition is made in the form of a single unit dosage form or a multiple unit dosage form comprising greater than about 720 mg of active agent calculated as mycophenolic acid.
- the present invention provides high dose solid unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium as active agent in an amount of from greater than about 720 mg to about 1500 mg, preferably from greater than about 800 mg to about 1440 mg, more preferably about 1080 mg calculated as mycophenolic acid, and one or more pharmaceutically acceptable excipient(s).
- the dosage form compositions provide the active agent in an extended release form which is released in a sustained manner in-vivo for a prolonged duration.
- the present invention provides high dose solid unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium as active agent in an amount of from greater than about 720 mg to about 1500 mg, preferably from greater than about 800 mg to about 1440 mg, more preferably about 1080 mg calculated as mycophenolic acid, and one or more pharmaceutically acceptable excipient(s), wherein the dosage form is coated using such composition which aids in providing a sustained release of the active agent.
- the present invention provides high dose solid unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium as active agent in an amount of about 1080 mg calculated as mycophenolic acid, and one or more pharmaceutically acceptable excipient(s), wherein the said active agent is present in an extended release form providing a sustained release of the active agent for a prolonged duration.
- the present invention provides high dose solid unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium as active agent in an amount of about 1080 mg calculated as mycophenolic acid, and one or more pharmaceutically acceptable excipient(s), wherein the total daily dose of mycophenolate sodium can be provided in a single unit dose such as a single once-a-day tablet or at the most two unit doses such as two tablets, that are easier to manufacture, and involves a low formulation cost.
- the present invention provides high dose solid unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium as active agent, optionally alongwith one or more pharmaceutically acceptable excipient(s), wherein the said composition is made in the form of a single unit dosage form or a multiple unit dosage form comprising greater than about 720 mg of active agent calculated as mycophenolic acid, and wherein the said single unit dosage form or a multiple unit dosage form is administrable at a dosing interval of at least about 12 hours.
- the recommended daily dose of Mycophenolate mofetil is 1 g to 3 g.
- the total daily dose of Mycophenolic acid in patients is 1440 mg which may extend upto a maximum of 2160 mg.
- patients are administered with four Myfortic® 180 mg tablets or two 360 mg tablet twice daily (1440 mg daily dose).
- a daily dose of 1 g to 3 g of Mycophenolate mofetil ( 1 g of Mycophenolate mofetil equivalent to 720 mg of MPA) is recommended for renal/ organ transplantation patients.
- Such a type of dosage regimen causes a lot of inconvenience for patients, and there are always chances that a dose is missed or a patient does not take so many tablets at a time.
- the present invention provides high dose solid unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium as active agent, optionally alongwith one or more pharmaceutically acceptable excipient(s), wherein the said composition is made in the form of a single unit dosage form or a multiple unit dosage form comprising greater than about 720 mg of active agent calculated as mycophenolic acid.
- the present invention provides high dose single unit modified release dosage form compositions comprising mycophenolate sodium as the active agent particularly as solid oral dosage forms, wherein the said dosage forms exhibit a sustained release of active agent throughout the GIT such that only a sufficient amount of the active agent is released in the lower part and/or proximal part of the gastro-intestinal tract so as to reduce the drug related gastrointestinal side effects without compromising the systemic bioavailability of the active agent.
- the high dose single unit modified release dosage form composition of the present invention is prepared by using formulation techniques aimed at releasing the immunosuppressant active agent in a manner such that the bioavailability of the dosage form thus obtained is at least comparable to a conventional immediate release dosage form.
- the release of mycophenolate sodium from the dosage form of the present invention is controlled in such a manner by using one or more release controlling materials alongwith one or more pharmaceutically acceptable excipient(s) so that therapeutically effective plasma concentration of the active agent can be obtained without any undesirable side effects for an extended period of time thus leading to improved patient compliance.
- the high dose single unit modified release dosage form composition comprises mycophenolate sodium as active agent in an amount of at least 30% by weight of the composition.
- the high dose single unit modified release composition is an extended release pharmaceutical composition according to the present invention which comprises mycophenolate sodium as the active agent in an amount of about 30% to about 99% by weight of the composition alongwith one or more release controlling material(s) in an amount of about 1% to about 70% by weight of the composition and one or pharmaceutically acceptable excipient(s) in an amount of about 0.5% to about 70% by weight of composition.
- the active agent of the present invention is mycophenolate sodium, e.g. mono or di-sodium salt, preferably mono-sodium salt.
- the release controlling material(s) useful in the present invention preferably comprises a polymeric material selected from but not limited to the group comprising pH dependent polymers such as alginates, carbomers, cellulose propionate (lower, medium or higher molecular weight), cellulose acetate propionate, cellulose acetate butyrate, cellulose triacetate or methacrylic acid polymers or a mixture thereof used either alone or in combination thereof; pH independent polymers such as acrylate or methacrylate polymers, or cellulosic polymers; soluble or insoluble polymers; swellable polymers; hydrophilic polymers; hydrophobic polymers; ionic polymers such as calcium carboxymethylcellulose or sodium carboxymethylcellulose; non-ionic polymers such as hydroxypropyl methylcellulose and its various pharmaceutically acceptable grades (e.g.
- pH dependent polymers such as alginates, carbomers, cellulose propionate (lower, medium or higher molecular weight), cellulose acetate propionate, cellulose acetate buty
- Methocel® KlOOM CR Methocel® KlOOM CR
- synthetic or natural polysaccharide selected from the group comprising alkylcelluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitrocelluloses, dextrin, agar, carrageenan, pectin, furcellaran, starch and starch derivatives, and mixtures thereof; cellulosic polymer, methacrylate polymer, carboxyvinyl polymer and its various pharmaceutically acceptable grades (e.g.
- Carbopol 71G Copolymers of acrylate and methacrylates with quarternary ammonium group (Eudragit®), polyvinylpyrrolidone (PVP), polyvinylpyrrolidone- polyvinylacetate polymer (PVP-PVA) copolymer, ethylcellulose, cellulose acetate, poly(alkyl methacrylate), poly ⁇ sodecyl methacrylate), poly ⁇ auryl methacrylate), poly(phenyl methacrylate), poly(alkyl acrylate), poly(octadecyl acrylate), poly(ethylene), poly(alkylene), poly(alkylene oxide), poly(alkylene terephthalate), poly( vinyl isobutyl ether), polyvinyl acetate), polyvinyl chloride) and polyurethane or a mixture thereof used either alone or in combination thereof.
- PVP polyvinylpyrrolidone
- PVP-PVA polyvinylpyrroli
- the release controlling material(s) useful in the present invention is a gum selected from but not limited to a group comprising xanthan gum, guar gum, gum arabic, carrageenan gum, karaya gum, locust bean gum, acacia gum, tragacanth gum, agar and the like or mixtures thereof used alone or in combination thereof.
- the release controlling material(s) useful in the present invention is a lipid agent selected from but not limited to a group comprising glyceryl behenate such as Compritol® ATO888, Compritol® HD ATO 5, and the like; hydrogenated vegetable oil such as hydrogenated castor oil e.g.
- the pharmaceutically acceptable excipient(s) useful in the composition of the present invention are selected from but not limited to a group of excipients generally known to persons skilled in the art e.g.
- diluents such as lactose (Pharmatose DCL 21), starch, mannitol, sorbitol, dextrose, microcrystalline cellulose, dibasic calcium phosphate, sucrose-based diluents, confectioner's sugar, monobasic calcium sulfate monohydrate, calcium sulfate dihydrate, calcium lactate trihydrate, dextrates, inositol, hydrolyzed cereal solids, amylose, powdered cellulose, calcium carbonate, glycine, and bentonite; disintegrants; binders; fillers; bulking agent; organic acid(s); colorants; stabilizers; preservatives; lubricants; glidants/antiadherants; chelating agents; vehicles; bulking agents; stabilizers; preservatives; hydrophilic polymers; solubility enhancing agents such as glycerin, various grades of polyethylene oxides, transcutol and glycofiirol; tonic
- the disintegrants useful in the present invention include but not limited to starch or its derivatives, partially pregelatinized maize starch (Starch 1500®), croscarmellose sodium, sodium starch glycollate, clays, celluloses, alginates, pregelatinized corn starch, crospovidone, gums and the like used either alone or in combination thereof.
- the lubricants useful in the present invention include but not limited to talc, magnesium stearate, calcium stearate, sodium stearate, stearic acid, hydrogenated vegetable oil, glyceryl behenate, glyceryl behapate, waxes, Stearowet, boric acid, sodium benzoate, sodium acetate, sodium chloride, DL-leucine, polyethylene glycols, sodium oleate, sodium lauryl sulfate, magnesium lauryl sulfate and the like used either alone or in combination thereof.
- the anti-adherents or glidants useful in the present invention are selected from but not limited to a group comprising talc, corn starch, DL-leucine, sodium lauryl sulfate, and magnesium, calcium and sodium stearates, and the like or mixtures thereof.
- the compositions may additionally comprise an antimicrobial preservative such as benzyl alcohol.
- the composition may additionally comprise a conventionally known antioxidant such as ascorbyl palmitate, butylhydroxyanisole, butylhydroxytoluene, propyl gallate and/or ⁇ -tocopherol.
- the dosage form of the present invention additionally comprises at least one wetting agent(s) such as a surfactant selected from a group comprising anionic surfactants, cationic surfactants, non-ionic surfactants, zwitterionic surfactants, or mixtures thereof.
- the wetting agents are selected from but not limited to a group comprising oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, sodium oleate, sodium lauryl sulfate and the like, or mixtures thereof.
- the dosage form of the present invention additionally comprises at least one complexing agent such as cyclodextrin selected from a group comprising but not limited to alpha-cyclodextrin, beta-cyclodextrin, betahydroxy-cyclodextrin, gamma-cyclodextrin, and hydroxypropyl beta-cyclodextrin, or the like.
- the dosage form of the present invention additionally comprises of lipid(s) selected from but not limited to glyceryl behenate such as Compritol® ATO888, Compritol® ATO 5, and the like; hydrogenated vegetable oil such as hydrogenated castor oil e.g.
- Lubritab® glyceryl palmitostearate such as Precirol® ATO 5 and the like, or mixtures thereof used either alone or in combination thereof. It will be appreciated that any given excipient may serve more than one function in the compositions according to the present invention.
- the present invention provides high dose single unit extended release pharmaceutical composition comprising mycophenolate sodium as the active agent; at least one pH independent polymer(s) and at least one lipid agent(s) as release controlling materials, optionally with one or more other pharmaceutically acceptable excipient(s).
- the present invention provides high dose single unit extended release pharmaceutical composition comprising mycophenolate sodium as the active agent; at least one pH independent polymer(s) and at least one gum(s) as release controlling materials, optionally with one or more other pharmaceutically acceptable excipient(s).
- Oral delivery of the high dose single unit pharmaceutical compositions of the present invention can include extended release formulations, providing prolonged or sustained delivery of the drug to the gastrointestinal tract by any number of mechanisms.
- Such prolonged or sustained release mechanisms can include, but are not limited to, pH sensitive release from the dosage form based on the changing pH of the gastro-intestinal tract; slow erosion of a tablet or capsule; retention in the stomach based on the physical properties of the formulation; bioadhesion of the dosage form to the mucosal lining of the intestinal tract; or enzymatic release of the active agent mycophenolate sodium from the dosage form.
- the intended effect is to extend the time period over which the active agent is delivered to site of action by manipulation of dosage form.
- Suitable matrix forming materials are waxes e.g., carnauba, bees wax, paraffin wax, ceresine, shellac wax, fatty acids, and fatty alcohols; oils, hardened oils or fats e.g., hardened rapeseed oil, castor oil, beef tallow, palm oil, and soya bean oil; polymers e.g., hydroxypropyl cellulose, hydroxyethyl cellulose, polyvinylpyrrolidone, hydroxypropyl methyl cellulose, polyethylene glycol, methacrylates (PMMA), polycarbophils and carbomers; alginates; gums e.g.
- waxes e.g., carnauba, bees wax, paraffin wax, ceresine, shellac wax, fatty acids, and fatty alcohols
- oils hardened oils or fats e.g., hardened rapeseed oil, castor oil, beef tallow, palm oil, and soya bean
- xanthan gum and other carrier materials known to those of ordinary skill in the art.
- suitable matrix tableting materials include, but are not limited to, microcrystalline cellulose, powdered cellulose, hydroxypropyl cellulose, and ethyl cellulose.
- Other types of extended release compositions may achieve controlled release by use of granulates, coated powders, pellets, or the like, by use of multi-layering, and/or by use of suitable coatings. Still other extended release compositions include an osmotic pump, or combinations of the above.
- Extended release compositions can be made by one or more techniques such as mixing, prilling, spray drying, pan coating, granulation, melt granulation, wurster coating, tangential coating, top spraying, tableting, extruding, coacervation and the like.
- the particle size of the extended release components other than active agent in the dosage form depends on the technology used. The particle sizes can range from submicron to 1000 micron for powder technologies (mixtures, spray drying, dispersions, and the like); 5-1900 microns for coating technologies (top spray, bottom spray, spray drying, extrusion, layering, and the like); and 0.1 microns to 50 mm for tableting technologies.
- the compositions can comprise the active agent in a micronized form. Where the composition is in the form of a pellet product, the pellets can be presented in a sachet, capsule or tablet.
- a plurality of elements containing active agent, or cores are prepared by extrusion/spheronization, or by layering the active agent (or a blend of active agent with other carrier materials) onto inert carriers by various processes.
- the cores can contain the active agent at the required potency according to the active agent dose, required size, required presentation, and subsequent processes (coating and the like).
- the cores can contain active agent in the range of about 0.1% to about 100%, depending on the required dose, potency, manufacturing method, and other properties.
- the controlled release form can be in the form of coated beads or granules of the active agent.
- the controlled release portion of the dose can be provided by a controlled release core as described above, or a controlled release core that is further modified by overcoating.
- the extended release compositions provide a therapeutic effect over a period greater than about 12 hours, with a sustained therapeutic effect for a period of about 12 to 24 hours being especially preferred.
- composition of the present invention is in the form of a tablet
- aqueous media such as in the gastrointestinal tract
- the tablet surface wets and the release controlling material(s) begins to partially hydrate forming an outer gel layer.
- This outer gel layer becomes fully hydrated and begins to erode into the aqueous fluids. Water continues to permeate toward the core of the tablet permitting another gel layer to form beneath the dissolving outer gel layer.
- These successive concentric gel layers sustain uniform release of the active agent by diffusion from the gel layer and exposure through tablet erosion. Changes in the tablet size and shape can affect the surface to volume ratio of the tablet and therefore the active agent release kinetics from the hydrophilic matrix of the tablet.
- the amount of mycophenolate sodium to be incorporated into the pharmaceutical composition of the present invention can vary over a wide range depending on known factors such as, for example, the intended use i.e. prophylactic or therapeutic, disease/disorder to be treated, the severity of the disease/disorder, the patient's body weight, the dosage form, the chosen route of administration and the number of administration per day. However, selection of optimum amount is simple and routine for a person skilled in the art. Typically the amount of mycophenolate sodium would be equivalent to about 720 mg to about 1500 mg of mycophenolic acid in a unit dose.
- the compositions of the present invention comprising mycophenolate sodium as active agent, releases the active agent throughout the gastro-intestinal tract (GIT).
- GIT gastro-intestinal tract
- the compositions are designed in such a manner so as to release a sufficient amount of the active agent in the lower part of the GIT and a substantial amount of the active agent in the upper part of the intestine, e.g. in the duodenum, jejunum and/or ileum.
- the release of mycophenolate sodium from the dosage form compositions of the present invention are designed in such a manner so that the said active is absorbed continuously throughout the GIT thus producing desired concentrations of the active in the blood and at the same time devoid of any substantial gastro-intestinal side effects associated with the active agent.
- compositions release the active agent in a manner such that it is effective, safe and well-tolerated particularly for immunosuppressive indications especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the treatment or prevention of immune-mediated diseases.
- the compositions of the present invention may be formulated to disintegrate or erode relatively slowly in the lower part of the GIT such as the stomach as compared to its disintegration or erosion in the upper part of the GIT.
- the present invention provides a modified release pharmaceutical composition
- a modified release pharmaceutical composition comprising particulate mycophenolate sodium having a D 90 particle size of about 0.001 to about 1000 microns, in an amount equivalent to about 720 mg to about 1500 mg of mycophenolic acid, at least one release controlling material(s), optionally alongwith one or more pharmaceutically acceptable excipient(s).
- the pharmaceutical composition according to the present invention comprises about 30% to about 99% by weight of mycophenolate sodium; about 0.001% to about 70% by weight of diluent(s); about 1% to about 70% by weight of release controlling material(s); about 0.1% to about 10% by weight of binder(s); and optionally about 0.1% to about 40% by weight of at least one lipophilic material(s) and optionally 0.01% to about 10% by weight of a lubricant.
- the lipophilic material(s) is present intragranularly or extragranularly or both intra and extragranularly, but more preferably extragranularly, alongwith the lubricant(s).
- the pharmaceutical composition according to the present invention comprises mycophenolate sodium in an amount equivalent to about 720 mg to about 1500 mg by weight of mycophenolic acid; about 0 mg to about 2000 mg by weight of diluent(s); about 1 mg to about 1000 mg by weight of release controlling polymer(s); about 0.1 mg to about 500 mg by weight of binder(s); and optionally about 1 mg to about 1000 mg by weight of at least one lipophilic material(s) and optionally about 1 mg to about 500 mg by weight of a lubricant(s).
- the release controlling material is an acrylate or a methacrylate polymer or copolymer, or a mixture of such polymers.
- the binder is an acrylate or a methacrylate polymer or copolymer, or a mixture of such polymers.
- the pharmaceutical composition comprises one or more material(s) selected from but not limited to a group comprising of a lipophilic material such as glyceryl behenate, an acrylate or a methacrylate polymer or copolymer such as Eudragit®; a cellulosic polymer such as hydroxypropyl methylcellulose; a gum such as xanthan gum; or suitable mixtures thereof.
- a lipophilic material such as glyceryl behenate, an acrylate or a methacrylate polymer or copolymer such as Eudragit®
- a cellulosic polymer such as hydroxypropyl methylcellulose
- a gum such as xanthan gum
- one or more of a material such as glyceryl behenate, an acrylate or a methacrylate polymer or copolymer such as Eudragit®, a cellulosic polymer such as hydroxypropyl methylcellulose, a gum such as xanthan gum, or mixtures thereof, is present as a lubricant composition which is added extragranularly to make the composition according to the present invention.
- the pharmaceutical composition is a coated or uncoated solid unit dosage form such as tablet.
- the modified release compositions of the present invention comprises a core and at least one coating such that the active agent mycophenolate sodium is either present in the core or the coat or in both.
- the coating also contributes in extending the release of the active agent from the compositions.
- the coating is applied on the core compositions from a solution and/or suspension preferably in an aqueous or an organic solvent.
- film-forming agents which are suitable for use in the coating composition in accordance with the present invention are agents selected from the group comprising of cellulose derivatives such as, e.g., ethylcellulose, cellulose acetate, cellulose propionate, cellulose butyrate, cellulose valerate, cellulose acetate propionate; methacrylic polymers; acrylic polymers such as, e.g., polymethyl methacrylate; vinyl polymers such as, e.g., polyvinyl acetate, polyvinyl formal, polyvinyl butyryl, vinyl chloride-vinyl acetate copolymer, vinyl acetate polymers and copolymers such as Kollicoat®SR 30D which is polyvinyl acetate (-27% w/w) stabilized with polyvinylpyrrolidone (-2-5% w/w) and sodium lauryl sulfate (-0.3% w/w), copolymer of polyvinyl alcohol-polyethylene glycol (Kolli
- the coating is not an enteric coating, but the coating composition is such that it controls the release of the active agent thus aiding the extended release of the active agent.
- the acrylic polymer is comprised of one or more ammonio methacrylate copolymers.
- the acrylic coating is an acrylic resin lacquer used in the form of an aqueous dispersion, such as that which is commercially available from Rohm Pharma under the tradename Eudragit®.
- the acrylic coating comprises a mixture of two acrylic resin lacquers such as Eudragit® RL 3OD and Eudragit® RS 3OD, which are copolymers of acrylic and methacrylic esters with a low content of quaternary ammonium groups.
- Eudragit® RIVRS mixtures are insoluble in water and in digestive fluids.
- coatings formed from the same are swellable and permeable in aqueous solutions and digestive fluids.
- Other polymers such as Eudragit® RL e.g. Eudragit® RLPO, and Eudragit® RS e.g. Eudragit® RSPO or their suitable mixtures can be used to obtain the extended release composition of the present invention having a desirable dissolution profile.
- a mixture of Eudragit® polymer and a cellulosic polymer such as hydroxypropyl methylcellulose can be used as the coating material.
- an extended release composition may also be prepared by using a retardant coating based on Eudragit® NE 3OD, which is a neutral resin.
- ethylcellulose or water-soluble coating materials such as water- soluble cellulose derivatives, e.g. hydroxypropylcellulose, carboxymethylcellulose, methylcellulose, propylcellulose, hydroxyethylcellulose, carboxyethylcellulose, carboxymethyl hydroxyethylcellulose, hydroxymelhylcellulose, carboxymethyl ethylcellulose, methylhydroxy propylcellulose or hydroxypropyl methylcellulose may be employed in the present invention.
- water- soluble cellulose derivatives e.g. hydroxypropylcellulose, carboxymethylcellulose, methylcellulose, propylcellulose, hydroxyethylcellulose, carboxyethylcellulose, carboxymethyl hydroxyethylcellulose, hydroxymelhylcellulose, carboxymethyl ethylcellulose, methylhydroxy propylcellulose or hydroxypropyl methylcellulose
- the amount of coating applied is adapted so as to obtain a predetermined dissolution characteristic of the novel extended release composition.
- the percentage by weight of the coating on the individual unit dosage form is about 2-30% w/w of the composition.
- the amount of coating applied depends on the predetermined dissolution characteristics of the particular core composition and the desired release profile. However, the amount of coating applied is such that there will be no rupturing problems.
- the coating may be admixed with various excipients selected from but not limited to a group comprising plasticizers, anti-adhesives such as, e.g., colloidal silicon dioxide, inert fillers, and pigments in a manner known per se.
- Tackiness of the water-dispersible film-forming substances may be overcome by simply incorporating an anti-adhesive in the coating.
- the anti-adhesive is preferably a finely divided, substantially insoluble, pharmaceutically acceptable non-wetting powder having anti-adhesive properties in the coating.
- anti-adhesives are metallic stearates such as magnesium stearate or calcium stearate, microcrystalline cellulose, or mineral substances such as calcite, substantially water-insoluble calcium phosphates or substantially water-insoluble calcium sulphates, colloidal silica, titanium dioxide, barium sulphates, hydrogenated aluminium silicates, hydrous aluminium potassium silicates and talc, or mixtures thereof.
- plasticizers for use in accordance with present invention .
- plasticizers include triacetin, acetylated monoglyceride, rape oil, olive oil, sesame oil, acetyl tributyl citrate, acetyl triethyl citrate, glycerin, sorbitol, diethyloxalate, diethylmalate, diethylmaleate, diethylfumarate, diethylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacetate, triethylcitrate, tributylcitrate, glyceroltributyrate, polyethyleneglycol, propyleneglycol, 1,2-propyleneglycol, dibutyl sebacate, diethyl sebacate, and mixtures thereof.
- the plasticizer is normally incorporated in an amount of less than about 20% by weight, calculated on dry matter content of coating composition.
- the coating may further comprise, especially in aqueous dispersions, one or more thickening agents to avoid sedimentation of suspended excipients, e.g. HPMC 3 cps or 6 cps and optionally anti-sticking agent e.g. colloidal silicon dioxide, a synthetic amorphous silicic acid such as Syloid 244 FP, talc, or glycerine monostearate, or their mixtures.
- compositions of the present invention comprising a substantially high dose of mycophenolate sodium in a single unit system that are safe, tolerable, effective and easy-to- manufacture had not been achieved earlier which was one of the major limitation of the prior art; however the inventors of the present invention have been able to alleviate said limitation(s) of the prior art and formulate novel compositions comprising a substantially high dose of mycophenolate sodium by virtue of extensive research and experimentation.
- the drug levels are maintained above the lower level of the prophylactic/therapeutic plasma concentration for longer periods of time.
- the oral extended release high dose compositions of the present invention are well-absorbed and possess other inherent advantages over conventional, immediate release dosage forms.
- a less frequent dosing of the medicament, as is required by a sustained release dosage form increases the resultant patient compliance, provides a more sustained drug blood level response, and effects therapeutic action with less ingestion of a drug, thereby mitigating many potential side effects.
- By providing a slow and steady release of mycophenolate sodium over time absorbed drug concentration spikes are mitigated or eliminated by affecting a smoother and more sustained blood level response.
- the extended release composition results in a uniform and constant dissolution of mycophenolate sodium from the pharmaceutical formulation and is thus effective for an extended period of time. Further, the extended release compositions are easy to formulate and the process of preparation is reproducible.
- the extended release compositions comprising mycophenolate sodium in a high dose as active agent in accordance with the invention characteristically releases the active agent in a sustained manner and the pharmaceutical activity maintains for a long period.
- the frequency of administration of mycophenolate sodium can be decreased. More particularly, it has become possible to provide a pharmaceutical formulation containing mycophenolate sodium which may be administered only once a day. Furthermore, it has become possible according to the present invention to provide a pharmaceutical composition which is free from the risk for undesired effects caused by a transiently excessive concentration of the active agent and insures an expression of pharmacological efficacy over a sufficiently extended time period.
- composition of the present invention which comprises treating mycophenolate sodium with one or more release controlling material(s), alongwith optionally one or more pharmaceutically acceptable excipient(s), and formulating into a suitable dosage form.
- a process of preparation of the modified release composition of the present invention which comprises treating the active agent mycophenolate sodium alongwith at least one release controlling material(s) which is hydrophilic or hydrophobic or mixtures thereof optionally alongwith one or more pharmaceutically acceptable excipient(s), and formulating into a suitable dosage form.
- the pharmaceutical composition of the present invention comprising mycophenolate sodium in a high dose is preferably formulated as an oral dosage form such as tablets, capsules, and the like.
- the composition of the present invention is in the form of tablets.
- the tablets can be prepared by either direct compression, dry compression (slugging), or by granulation.
- the granulation technique is either aqueous or non-aqueous.
- the non-aqueous solvent used is selected from a group comprising ethanol, isopropyl alcohol, acetone or methylene chloride.
- the compositions of the present invention are in the form of compressed tablets, molded tablets, or products prepared by extrusion or film cast technique, and the like.
- the composition of the present invention may be in the particulate form such a powder, granules, beads, pellets, mini-tablets or the like, preferably made into a single unit dosage form such as a tablet or capsule.
- the compositions may be coated with a 'functional coating'.
- 'functional coating' it is herein implied that the coating composition does not comprise of a enteric polymer but comprises a part of the active agent(s) and/or the composition comprises excipient(s) which aid in controlling the rate of release of the active agent(s) independent of the pH through GIT pHs and/or the composition comprises additionally another active agent which is different from the active agent present in the core composition.
- the coating composition employed may be an aqueous, non-aqueous or a hydro-alcoholic system.
- the solvents used to prepare a non-aqueous coating composition is selected from but not limited to a group comprising dehydrated alcohol, isopropyl alcohol, methylene chloride, acetone or any other solvent known to the art for such use, or mixtures thereof.
- the coating composition can include an antitack agent such as talc, kaolin, titanium dioxide, silicon dioxide, alumina, starch, polacrilin potassium, microcrystalline cellulose or the like.
- the composition comprises a high dose of mycophenolate sodium and comparatively lesser excipients
- the mechanical strength of the composition according to the present invention is sufficiently high to withstand normal handling of a pharmaceutical composition and to enable the composition to be coated using traditional coating equipments well known to a person skilled in the art.
- the pharmaceutical compositions of the present invention are intended for once-a-day or twice-a-day administration, preferably for once-a-day administration.
- the once-a-day composition releases mycophenolate sodium in a desired manner so as to maintain prophylactic and/or therapeutic levels of the active agent in the plasma for extended period of time devoid of any substantial drug related toxicity, and also can be prepared in an easy and cost-effective manner.
- the ..present -invention provides , once ⁇ a-day modified release ⁇ compositions ⁇ comprising mycophenolate sodium in high dose such that the inter- and intra-patient variability is alleviated or reduced.
- the modified release mycophenolate sodium compositions of the present invention are stable, possess appreciable bioavailability characteristics, and are well-tolerated and safe.
- the oral compositions comprising mycophenolate sodium for prophylactic and/or therapeutic use can release the drug in a desired manner such as to maintain prophylactic/therapeutic levels of the drug in the plasma for extended period of time but without causing drug related toxicity; and which can be prepared in an easy and cost-effective manner.
- the single unit dosage form composition of the present invention comprising a high dose of mycophenolate sodium is a tablet.
- oral solid dosage forms e.g. effervescent tablets, fast dispersible tablets, matrix tablets, minitablets, pulsed release tablets, pellets, capsules, granulates or powders, e.g. in a sachet or a bottle, may be produced and are encompassed within the scope of this invention.
- the tablets of the present invention are, despite the high drug loading of at least about 10% by weight based on the total weight of the tablet, are convenient to administer. Furthermore, the tablets are stable, e.g. during storage, handling or packaging, effective and well-tolerated.
- the tablets have improved mechanical properties; e.g. when uncoated tablets are scored, they are easy to divide to produce e.g. half doses.
- the tablets obtained are stable both during the production process and during storage, e.g. for 2 years or even 3 years in conventional packaging.
- the present invention provides an oral solid dosage form, e.g. tablet, wherein the mycophenolate sodium salt is in anhydrous or crystalline form or a mixture of both forms.
- the tablet according to the present invention it is a characteristic of the tablet according to the present invention that despite the high content of mycophenolate sodium, it contains only a relatively small amount of pharmaceutically acceptable excipient(s). This advantageously results in a mechanically stable tablet having a size amenable to oral administration.
- the total amount of one or more pharmaceutically acceptable excipient(s) in a given unit dosage form according to the present invention may be not more than about 80% by weight based on the total weight of the tablet.
- the absolute amounts of each pharmaceutically acceptable excipient(s) and their relative amounts are dependent on the desired properties of the tablet and may also be chosen by routine experimentation.
- the tablet may be chosen to exhibit accelerated release of the active agent mycophenolate sodium or an extended release of the said active agent.
- the tablet is chosen to -exhibit an extended release of the mycophenolate sodium over a prolonged time period.
- compositions may be in the form of oral osmotic systems (OROS), coated tablets, matrix tablets, press-coated tablets, rapidly disintegrating tablets and the like.
- OROS oral osmotic systems
- the compositions comprising a high dose of mycophenolate sodium may be preferably made as coated tablets.
- the tablet compositions of the present invention may also be produced by direct compression of mycophenolate sodium and one or more pharmaceutically acceptable excipient(s). Alternatively granulation techniques such as melt granulation, wet granulation (aqueous or organic solvent) or roller compaction may be performed, followed by the compression step. Optionally the tablets may be film-coated using conventional coating equipments and methods.
- the activity and characteristics of the high dose solid unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium of the present invention may be indicated in standard animal trials e.g. observing the kidney allograft reaction in rat may be employed. Additionally, clinical trials e.g. observing the first acute rejection episodes or treatment failure six months after transplant of kidneys or maintaining a rejection-free state within 6 months after initiation of treatment with the invention might be conducted to substantiate the animal experiments.
- the composition of the present invention additionally comprises at least one other active agent(s).
- the other active agent useful in the present invention may be any agent known to the art that can be administered in combination with a immunosuppressant such as an active agent(s) selected from but not limited to a group comprising cardiovascular drug, respiratory drug, sympathomimetic drug, cholinomimetic drug, adrenergic agonist, adrenergic antagonist, analgesic/antipyretic, anesthetic, antiasthamatic, antibiotic, antidepressant, antidiabetic, antifungal, antihypertensive, anti-inflammatory, antineoplastic, antianxiety agent, antipsychotic, immunosuppressant, antimigraine agent, sedative/hypnotic, antianginal agent, antiarrhythmic, antiarthritic agent, antigout agent, anticoagulant, thrombolytic agent, antifibrinolytic agent, hemorheologic agent, antiplatelet agent, anticonvulsant, antiparkin
- the other active agent useful in the present invention alongwith mycophenolate sodium is an immunosuppressant such as cyclosporine or a corticosteroid.
- the present invention provides a method of immunosuppressing a subject which comprises administering a solid dosage form according to the present invention, e.g. a tablet, to a subject in need of such immunosuppression, optionally with the simultaneous, sequential or separate administration of another immunosuppressant or immunomodulatory compound, such as cyclosporine and/or a steroid.
- the high dose solid unit oral pharmaceutical dosage form compositions comprising mycophenolate sodium are provided in unit dosage form wherein the core comprises mycophenolate sodium mixed in suitable proportions alongwith pharmaceutically acceptable excipients and may be prepared by any of the methods well-known in the pharmaceutical art.
- the present invention provides use of the pharmaceutical composition comprising a high dose of mycophenolate sodium according to the present invention in reducing the variability in absorption of mycophenolate sodium throughout the gastro-intestinal tract by providing a substantially uniform sustained release in-vivo and also reducing the chances of causing any associated gastrointestinal side effects without compromising the bioavailability of said active agent.
- a method of using the composition of the present invention comprising a high dose of mycophenolate sodium for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the management of immune-mediated diseases (autoimmune diseases), which comprises administering to a subject in need thereof the composition comprising a pharmaceutically effective amount of mycophenolate sodium as the active agent.
- autoimmune diseases immune-mediated diseases
- the pharmaceutical composition comprising pharmaceutically effective amount of mycophenolate sodium as the active agent for the preparation of a medicament for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the management of immune-mediated diseases (autoimmune diseases).
- a medicament for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the management of immune-mediated diseases (autoimmune diseases).
- compositions of the present invention comprising a high dose of mycophenolate sodium are useful in the treatment and/or prevention of native or transgenic organ, tissue or cellular allograft or xenograft transplant rejection, e.g. for the treatment of recipients of e.g. heart, lung, combined heart-lung, liver, kidney, pancreatic, skin, pancreatic islet cell, neural cell or corneal transplant; including treatment and prevention of acute rejection; treatment and prevention of hyperacute rejection, e.g. as associated with xenograft rejection; and treatment and prevention of - chronic rejection r e.gr as-associated -with-graft- vessel disease.
- the compositions of the -invention are also indicated for the treatment and prevention of graft-versus-host disease, such as following bone marrow transplantation.
- compositions of the present invention comprising a high dose of mycophenolate sodium in a single unit system are also useful in the treatment and/or prevention of autoimmune diseases, e.g. immune-mediated diseases and inflammatory conditions, in particular inflammatory conditions with an etiology including an immunological component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases.
- autoimmune diseases e.g. immune-mediated diseases and inflammatory conditions, in particular inflammatory conditions with an etiology including an immunological component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases.
- compositions of the invention include, autoimmune hematological disorders, including, but not limited to hemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia), systemic lupus erythematosus, polychondritis, sclerodoma, Wegener granulosis, dermatomyositis, polymyositis, chronic active hepatitis, primary bilary cirrhosis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, pemphigus, idiophatic sprue, inflammatory bowel diseases (including e.g.
- ulcerative colitis and Crohn's disease endocrine ophthalmophathy
- Graves disease sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes (diabetes mellitus type I), non-infectious uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis, vasculitides, glomerulonephritides (with and without nephrotic syndrome, e.g. including idiophatic nephrotic syndrome or minimal change nephropathy) and juvenile dermatomyositis.
- step (ii) Polyvinyl pyrrolidone (PVP K-30) was weighed and dissolved in isopropyl alcohol under stirring, iii) The blend of step (iii) was granulated using the solution of step (ii), dried and passed through suitable sieves to obtain granules, iv) Step (iii) granules were lubricated with mesh #40 passed magnesium stearate and compressed to obtain tablets.
- PVP K-30 Polyvinyl pyrrolidone
- step (i) Mycophenolate sodium, lactose anhydrous, hydroxypropyl methylcellulose, polyethylene oxide and polyvinyl pyrrolidone k-90 were weighed and mixed together, ii) Polyvinylpyrrolidone K-30 was dissolved in isopropyl alcohol, iii) The blend of step (i) was granulated with the material of step (ii) and then passed through sieve of mesh size # 12 followed by drying. iv) The dried material was passed through sieve of mesh size # 24. v) The material of step (iv) was lubricated with sieve of mesh size # 60 passed magnesium stearate for 5 mins. vi) The lubricated granules of step (v) were compressed into tablet.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention porte sur des compositions de forme posologique pharmaceutique à usage oral unitaire solide à haute dose comprenant, comme agent actif, une quantité de mycophénolate de sodium se situant entre plus de 720 mg environ et 1500 mg environ, de préférence entre 800 mg et 1 440 mg environ, calculée comme acide mycophénolique ; et un ou plusieurs excipients pharmaceutiquement acceptables. Plus spécifiquement, les compositions de forme posologique sont destinées à être administrées une ou deux fois par jour et délivrent un agent actif à libération prolongée libéré de façon soutenue in vivo pendant une durée prolongée. L'invention porte également sur un procédé de fabrication des formulations à haute dose et sur des procédés prophylactiques et/ou thérapeutiques d'utilisation de telles formes posologiques. La composition de la présente invention est facile à formuler, efficace, bien tolérée et ne présente pas de danger. Ladite composition est utile pour la gestion -prophylaxie et amélioration, par exemple- et/ou pour le traitement de maladies/troubles requérant des immunosuppresseurs, notamment pour le traitement ou la prévention d'un rejet d'allogreffe ou de xénogreffe d'organe, de tissu ou de cellule après transplantation, par exemple, ou pour la gestion de maladies immunoinduites (maladies autoimmunes).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2107DE2007 | 2007-10-08 | ||
IN2107/DEL/2007 | 2007-10-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009047799A1 true WO2009047799A1 (fr) | 2009-04-16 |
Family
ID=40548981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2008/000651 WO2009047799A1 (fr) | 2007-10-08 | 2008-10-08 | Forme posologique pharmaceutique à usage oral unitaire solide à haute dose de mycophénolate de sodium et son procédé de fabrication |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR068745A1 (fr) |
CL (1) | CL2008002984A1 (fr) |
WO (1) | WO2009047799A1 (fr) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011046546A1 (fr) * | 2009-10-13 | 2011-04-21 | Teva Pharmaceutical Industries Ltd. | Compositions à libération retardée |
BE1018740A3 (nl) * | 2010-08-10 | 2011-07-05 | Oystershell Nv | Samenstelling voor de behandeling van vochtige epitheliale oppervlakken. |
CN102793658A (zh) * | 2012-08-23 | 2012-11-28 | 无锡福祈制药有限公司 | 一种含有麦考酚酸或麦考酚酸盐的骨架型制剂及其包衣片 |
US8361971B2 (en) | 2010-06-07 | 2013-01-29 | Telik, Inc. | Tablet formulation of ezatiostat |
US8759303B2 (en) | 2010-06-07 | 2014-06-24 | Telik, Inc. | Compositions and methods for treating myelodysplastic syndrome |
US8841476B2 (en) | 2010-06-07 | 2014-09-23 | Telik, Inc. | Preparation of crystalline ezatiostat hydrochloride ansolvate form D |
WO2014167442A1 (fr) | 2013-03-26 | 2014-10-16 | Wockhardt Limited | Compositions pharmaceutiques comprenant de l'acide mycophénolique ou des sels de celui-ci |
US8920838B2 (en) | 2006-08-03 | 2014-12-30 | Horizon Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid disease |
WO2018093289A1 (fr) * | 2016-11-17 | 2018-05-24 | Общество с ограниченной ответственностью "Изварино Фарма" | Formulation orale solide et procédé de fabrication correspondant |
CN110787206A (zh) * | 2019-12-23 | 2020-02-14 | 卓和药业集团有限公司 | 一种含有麦考酚钠的药物组合物及其制备方法 |
RU2723255C2 (ru) * | 2018-11-14 | 2020-06-09 | Общество с ограниченной ответственностью "Изварино Фарма" | Экструдат с микофенолятом натрия для получения пероральной твердой лекарственной формы |
CN114569570A (zh) * | 2022-03-15 | 2022-06-03 | 浙江长典药物技术开发有限公司 | 一种吗替麦考酚酯及制备方法 |
CN115192597A (zh) * | 2022-08-08 | 2022-10-18 | 青海大学 | 用于防治肺动脉高压的药物组合物、其制备方法及应用 |
CN117442580A (zh) * | 2023-12-21 | 2024-01-26 | 泊诺(天津)创新医药研究有限公司 | 一种高生物利用度麦考酚钠肠溶片及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994026266A1 (fr) * | 1993-05-13 | 1994-11-24 | Syntex (U.S.A.) Inc. | Formules a dose eleves |
WO2006024479A2 (fr) * | 2004-08-31 | 2006-03-09 | Novartis Ag | Compositions pharmaceutiques |
WO2007093364A1 (fr) * | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Nouvelles aryldihydroisoquinolinones à substitution azacyclyle, leur procédé de préparation et leur utilisation comme médicaments |
-
2008
- 2008-10-07 AR ARP080104384A patent/AR068745A1/es not_active Application Discontinuation
- 2008-10-08 WO PCT/IN2008/000651 patent/WO2009047799A1/fr active Application Filing
- 2008-10-08 CL CL2008002984A patent/CL2008002984A1/es unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994026266A1 (fr) * | 1993-05-13 | 1994-11-24 | Syntex (U.S.A.) Inc. | Formules a dose eleves |
WO2006024479A2 (fr) * | 2004-08-31 | 2006-03-09 | Novartis Ag | Compositions pharmaceutiques |
WO2007093364A1 (fr) * | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Nouvelles aryldihydroisoquinolinones à substitution azacyclyle, leur procédé de préparation et leur utilisation comme médicaments |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9504699B2 (en) | 2006-08-03 | 2016-11-29 | Hznp Limited | Delayed-release glucocorticoid treatment of rheumatoid disease |
US8920838B2 (en) | 2006-08-03 | 2014-12-30 | Horizon Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid disease |
WO2011046546A1 (fr) * | 2009-10-13 | 2011-04-21 | Teva Pharmaceutical Industries Ltd. | Compositions à libération retardée |
US8759303B2 (en) | 2010-06-07 | 2014-06-24 | Telik, Inc. | Compositions and methods for treating myelodysplastic syndrome |
US8841476B2 (en) | 2010-06-07 | 2014-09-23 | Telik, Inc. | Preparation of crystalline ezatiostat hydrochloride ansolvate form D |
US8361971B2 (en) | 2010-06-07 | 2013-01-29 | Telik, Inc. | Tablet formulation of ezatiostat |
BE1018740A3 (nl) * | 2010-08-10 | 2011-07-05 | Oystershell Nv | Samenstelling voor de behandeling van vochtige epitheliale oppervlakken. |
CN102793658A (zh) * | 2012-08-23 | 2012-11-28 | 无锡福祈制药有限公司 | 一种含有麦考酚酸或麦考酚酸盐的骨架型制剂及其包衣片 |
WO2014167442A1 (fr) | 2013-03-26 | 2014-10-16 | Wockhardt Limited | Compositions pharmaceutiques comprenant de l'acide mycophénolique ou des sels de celui-ci |
WO2018093289A1 (fr) * | 2016-11-17 | 2018-05-24 | Общество с ограниченной ответственностью "Изварино Фарма" | Formulation orale solide et procédé de fabrication correspondant |
RU2723255C2 (ru) * | 2018-11-14 | 2020-06-09 | Общество с ограниченной ответственностью "Изварино Фарма" | Экструдат с микофенолятом натрия для получения пероральной твердой лекарственной формы |
CN110787206A (zh) * | 2019-12-23 | 2020-02-14 | 卓和药业集团有限公司 | 一种含有麦考酚钠的药物组合物及其制备方法 |
CN114569570A (zh) * | 2022-03-15 | 2022-06-03 | 浙江长典药物技术开发有限公司 | 一种吗替麦考酚酯及制备方法 |
CN114569570B (zh) * | 2022-03-15 | 2023-03-24 | 浙江长典药物技术开发有限公司 | 一种吗替麦考酚酯及制备方法 |
CN115192597A (zh) * | 2022-08-08 | 2022-10-18 | 青海大学 | 用于防治肺动脉高压的药物组合物、其制备方法及应用 |
CN117442580A (zh) * | 2023-12-21 | 2024-01-26 | 泊诺(天津)创新医药研究有限公司 | 一种高生物利用度麦考酚钠肠溶片及其制备方法 |
CN117442580B (zh) * | 2023-12-21 | 2024-04-05 | 泊诺(天津)创新医药研究有限公司 | 一种高生物利用度麦考酚钠肠溶片及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CL2008002984A1 (es) | 2009-06-05 |
AR068745A1 (es) | 2009-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009047799A1 (fr) | Forme posologique pharmaceutique à usage oral unitaire solide à haute dose de mycophénolate de sodium et son procédé de fabrication | |
US9642808B2 (en) | Extended release compositions comprising mycophenolate sodium and processes thereof | |
US20200000726A1 (en) | Gastroresistant pharmaceutical formulations containing rifaximin | |
US20110008426A1 (en) | Modified release pharmaceutical compositions comprising mycophenolate and processes thereof | |
EP1438040B1 (fr) | Compositions pharmaceutiques comprenant de l'acide mycophenolique ou un sel mycophenolate | |
WO2008132710A2 (fr) | Compositions pharmaceutiques à base de nimodipine | |
US20020031550A1 (en) | Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3yl) acetonitrile monohydrochloride | |
MXPA06003646A (es) | Composicion farmaceutica de multi-particulas que comprende acido micofenolico o micofenolato de sodio y combinacion con rapamicina. | |
PL192273B1 (pl) | Preparat środka leczniczego w postaci pastylki o kontrolowanej dyfuzji lub w postaci układu matrycowego, o kontrolowanym uwalnianiu substancji czynnej | |
JP2665858B2 (ja) | 持効性塩酸オキシブチニン製剤 | |
KR101925590B1 (ko) | 개선된 생체이용률을 갖는 페노피브릭산 제제 | |
US20100272794A1 (en) | Pharmaceutical composition of memantine | |
WO2022061058A1 (fr) | Formes posologiques multiparticulaires comprenant de la deutétrabenazine | |
WO2008001311A2 (fr) | Composition pharmaceutique associant une dose fixe d'aténolol et une dose fixe de mononitrate d'isosorbide | |
WO2023044024A1 (fr) | Nouveau système d'administration de médicament à revêtement dépendant du ph |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08838387 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08838387 Country of ref document: EP Kind code of ref document: A1 |